Update on CYP2D6 and its impact on tamoxifen therapy.
Mayo Clinic, Rochester, MN, USA.
Matthew P
MP
Goetz
D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D002986:Clinical Trials as Topic; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism* / Q000627:therapeutic use; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C055492:4-hydroxy-N-desmethyltamoxifen; D019389:Cytochrome P-450 CYP2D6